Pfizer, Sangamo dose first subject in Phase 3 haemophilia A trial
Pfizer and its partner Sangamo Therapeutics have dosed the first participant in the Phase 3 AFFINE study, evaluating giroctocogene fitelparvovec, a potential gene therapy for haemophilia A. The